[1. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm. 2004;61(22):2391–9.10.1093/ajhp/61.22.239115581262]Search in Google Scholar
[2. Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005;90 Suppl 1:i26-9.10.1136/adc.2004.059386176527015665154]Search in Google Scholar
[3. Sauer J-M, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571–90.10.2165/00003088-200544060-0000215910008]Search in Google Scholar
[4. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos. 2002 ;30(3):319–23.10.1124/dmd.30.3.31911854152]Search in Google Scholar
[5. Yu G, Li G-F, Markowitz JS. Atomoxetine: A review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016;26(4):314-26.10.1089/cap.2015.0137487652926859445]Search in Google Scholar
[6. Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011;50(5):281–94.10.2165/11539240-000000000-0000021366359]Search in Google Scholar
[7. Wernicke JF, Gahimer J, Yalcin I, Wulster-radcliffe M, Viktrup L. Safety and adverse event profile of duloxetine. Expert Opin Drug Saf. 2005;4(6):987-93.10.1517/14740338.4.6.98716255658]Search in Google Scholar
[8. Carter NJ, McCormack PL. Duloxetine: A review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523–41.10.2165/00023210-200923060-0000619480470]Search in Google Scholar
[9. Sobanski E, Paslakis G, Schredl M et al. Managing ADHD in adults with common comorbidities. In: Surman C, ed. ADHD in adults. A practical guide to evaluation and managament. Current Clinical Psychiatry. Totowa, NJ: Humana Press; 2013. p. 137–54.10.1007/978-1-62703-248-3_8]Search in Google Scholar
[10. Bond DJ, Hadjipavlou G, Lam RW et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry. 2012;24(1):23–37.]Search in Google Scholar
[11. Kooij JJS, Bijlenga D, Salerno L et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019;56:14–34.10.1016/j.eurpsy.2018.11.00130453134]Search in Google Scholar
[12. Dodangi N, Habibi N, Astaneh AN. Preliminary investigation on duloxetine efficacy in the treatment of children with attention-deficit hyperactivity disorder. J Compr Pediatr. 2015; 6(4):e27482. doi: 10.17795/compreped-27482.10.17795/compreped-27482]Search in Google Scholar
[13. Niederhofer H. Duloxetine may improve some symptoms of attention-deficit/hyperactivity disorder. Prim Care Companion J Clin Psychiatry. 2010;12(2): PCC.09l00807. doi: 10.4088/PCC.09l00807pin.10.4088/PCC.09l00807pin]Open DOISearch in Google Scholar
[14. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.10.3758/BF03193146]Search in Google Scholar
[15. Todor I, Popa A, Neag M et al. Evaluation of the potential pharmacokinetic interaction between atomoxetine and fluvoxamine in healthy volunteers. Pharmacology. 2017;99(1-2):84-88.10.1159/000452223]Search in Google Scholar
[16. Todor I, Popa A, Neag M et al. Evaluation of a potential metabolism-mediated drug-drug interaction between atomoxetine and bupropion in healthy volunteers. J Pharm Pharm Sci. 2016;19(2):198–207.10.18433/J3H03R]Search in Google Scholar
[17. Todor I, Popa A, Neag M et al. The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. Clujul Med. 2015;88(4):513-520.10.15386/cjmed-488]Search in Google Scholar
[18. Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet.2015;387(10024):1240–50.10.1016/S0140-6736(15)00238-X]Search in Google Scholar
[19. Biederman J, Petty CR, Evans M, Small J, Faraone S V. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res. 2010;177(3):299–304.10.1016/j.psychres.2009.12.010288183720452063]Search in Google Scholar
[20. Faraone S V, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159–65.10.1017/S003329170500471X16420712]Search in Google Scholar
[21. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9(3):490–9.10.1007/s13311-012-0135-8344193622976615]Search in Google Scholar
[22. Fayyad J, De Graaf R, Kessler R et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402–9.10.1192/bjp.bp.106.03438917470954]Search in Google Scholar
[23. Wang B, Yang L-P, Zhang XZ, Huang SQ, Bartlam M, Zhou SF. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev. 2009;41(4):573–643.10.1080/0360253090311872919645588]Search in Google Scholar
[24. Lin ND, Norman H, Regev A et al. Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database. BMC Gastroenterol. 2015; 15:134. doi: 10.1186/s12876-015-0373-4.10.1186/s12876-015-0373-4460716926467777]Open DOISearch in Google Scholar
[25. Belle DJ, Ernest CS, Sauer J, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol. 2002;42(11):1219-27.10.1177/00912700276249130712412820]Search in Google Scholar
[26. Childress AC. A critical appraisal of atomoxetine in the management of ADHD. Ther Clin Risk Manag. 2015; 12:27-39.10.2147/TCRM.S59270469469326730199]Search in Google Scholar
[27. Fredriksen M, Halmøy A, Faraone S V, Haavik J. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD : A review of controlled and naturalistic studies. Eur Neuropsychopharmacol. 2013;23(6):508-27.10.1016/j.euroneuro.2012.07.01622917983]Search in Google Scholar
[28. Hennissen L, Bakker MJ, Banaschewski T et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD : a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs. 2017;31(3):199–215.10.1007/s40263-017-0410-7533654628236285]Search in Google Scholar
[29. Kasi PM, Mounzer R, Gleeson GH. Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system. Case Rep Med. 2011;2011:952584. doi: 10.1155/2011/952584.10.1155/2011/952584313522521765848]Search in Google Scholar